Bentley, Dong Sung Enter into Licensing Agreement for Clinical Development

Bentley Pharmaceuticals has entered into an agreement with Dong Sung Pharmaceuticals for the development of an intranasal spray formulation of insulin for the South Korean market and possibly additional territories.

The agreement is Bentley's first to develop and license its intranasal spray formulation of insulin. Under the agreement, the two companies have agreed to conduct Phase II and Phase III studies designed to comply with international standards that would be applicable for regulatory submissions in South Korea and possibly in other countries.

A joint working team consisting of Bentley and Dong Sung employees, as well as consultants, will guide the development process in Korea. Dong Sung will fund the appropriate studies and submit the regulatory documents required for their licensed territory. Bentley will provide clinical and commercial supplies of insulin formulations, as well as metered administration devices.